We found that genetic deletion or pharmacologic inhibition of the NLRP3 inflammasome did not ameliorate any of the histological components of fibrosing NASH in HFHC-fed mice. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.